On Monday, Piper Sandler adjusted the stock price target for Cytek Biosciences Inc (NASDAQ:CTKB), decreasing it to $8.25 from the previous $8.50, while maintaining an Overweight rating on the stock.

TAMPA, FL - TuHURA Biosciences Inc. (NASDAQ:HURA) announced significant advancements in its pipeline of cancer immunotherapies, including an upcoming Phase 3 trial for its leading drug candidate IFx-2 ...

The value of this transaction also fell within the $15,001 to $50,000 range. A significant event occurred on October 18, 2024, when a note held by Lee in TuHURA Biosciences Inc. (NASDAQ:HURA) was ...

isa_ozdere / Getty Images IOTA is a distributed ledger platform designed for the Internet of Things, enterprise needs, eHealth, and digital identity ecosystems. Its native token, IOTA ...

On the buying side, ARK showed continued interest in Pacific Biosciences (NASDAQ:PACB) of California Inc (NASDAQ:PACB), acquiring 33,764 shares across its ARKK and ARKG ETFs, valued at $58,074. This ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company focused on developing therapies for Duchenne muscular dystrophy (DMD), stands at a critical juncture in its journey to bring a ...

CAMBRIDGE, Mass. - Enveric Biosciences Inc. (NASDAQ: ENVB), a biotechnology company specializing in the development of treatments for mental health disorders, has entered into a licensing agreement ...